アミロイドーシス（Amyloidosis）：グローバル臨床試験レビュー（2014年上半期）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Amyloidosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Amyloidosis to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Amyloidosis to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Amyloidosis 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Amyloidosis Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Amyloidosis 33
Jan 09, 2014: BELLUS Health provides update on KIACTA Phase III orphan drug study 33
Dec 24, 2013: Widely-used anti-inflammatory drug shows success in treatment of amyloidosis 33
Dec 16, 2013: Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic Targeting Transthyretin in Development for the Treatment of TTR-Mediated Amyloidosis 34
Nov 10, 2013: Alnylam Reports Positive Phase II Data for Patisiran, an RNAi Therapeutic Targeting Transthyretin for the Treatment of TTR-Mediated Amyloidosis, and Initiates Phase III Trial 35
Sep 30, 2013: Alnylam Completes Enrollment of Phase II Clinical Trial and Initiates Open-Label Extension (OLE) Study with ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidos 37
Clinical Trial Profiles 39
Clinical Trial Overview of Top Companies 39
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Alnylam Pharmaceuticals, Inc. 40
Clinical Trial Overview of Alnylam Pharmaceuticals, Inc. 40
Celgene Corporation 41
Clinical Trial Overview of Celgene Corporation 41
GlaxoSmithKline plc 42
Clinical Trial Overview of GlaxoSmithKline plc 42
Takeda Pharmaceutical Company Limited 43
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 43
Isis Pharmaceuticals, Inc. 44
Clinical Trial Overview of Isis Pharmaceuticals, Inc. 44
Prothena Corporation plc 45
Clinical Trial Overview of Prothena Corporation plc 45
Bellus Health Inc. 46
Clinical Trial Overview of Bellus Health Inc. 46
C.T. Development America, Inc. 47
Clinical Trial Overview of C.T. Development America, Inc. 47
Clinical Trial Overview of Top Institutes / Government 48
Boston Medical Center 48
Clinical Trial Overview of Boston Medical Center 48
Mayo Clinic 49
Clinical Trial Overview of Mayo Clinic 49
National Cancer Institute 50
Clinical Trial Overview of National Cancer Institute 50
Stanford University 51
Clinical Trial Overview of Stanford University 51
Boston University 52
Clinical Trial Overview of Boston University 52
IRCCS Policlinico San Matteo 53
Clinical Trial Overview of IRCCS Policlinico San Matteo 53
IRCCS Policlinico S. Donato 54
Clinical Trial Overview of IRCCS Policlinico S. Donato 54
Memorial Sloan Kettering Cancer Center 55
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 55
Umea University 56
Clinical Trial Overview of Umea University 56
Southwest Oncology Group 57
Clinical Trial Overview of Southwest Oncology Group 57
Five Key Clinical Profiles 58
Appendix 108
Abbreviations 108
Definitions 108
Research Methodology 109
Secondary Research 109
About GlobalData 110
Contact Us 110
Disclaimer 110
Source 110